Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000056N5

Price
44.47 CNY
Market cap
4.86 bn CNY
P/E (2025)
–
P/S (2025)
7.16
Dividend yield
0.00 %
Net margin
-13.33 %
Return on equity (ROE)
-3.63 %
Return on assets (ROA)
-2.45 %

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. financials

Fiscal year20242025
Revenue801.92 m CNY677.99 m CNY
Gross profit416.86 m CNY267.83 m CNY
Operating income16.40 m CNY-25.74 m CNY
EBIT-19.12 m CNY-70.12 m CNY
Net income-52.74 m CNY-90.40 m CNY
Diluted EPS – continuing operations-0.48 CNY-0.83 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications. Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. was incorporated in 2011 and is headquartered in Hangzhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.